Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review
B-cell acute lymphoblastic leukemia (B-ALL) with the MLL-AF4 fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). Herein, we present a case of a 46-year-old male patient who developed relapsed B-ALL with MLL-AF4. The patient ini...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1475974/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841540140251480064 |
|---|---|
| author | Xuelian Jin Zhigang Liu Yu Wu Jie Ji |
| author_facet | Xuelian Jin Zhigang Liu Yu Wu Jie Ji |
| author_sort | Xuelian Jin |
| collection | DOAJ |
| description | B-cell acute lymphoblastic leukemia (B-ALL) with the MLL-AF4 fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). Herein, we present a case of a 46-year-old male patient who developed relapsed B-ALL with MLL-AF4. The patient initially achieved a complete remission (CR) after induction therapy and underwent haploidentical hematopoietic stem cell transplantation. Five months post-transplantation, he developed enlarged lymph nodes and subcutaneous masses. A lymph node biopsy confirmed EMR, without leukemia in the bone marrow or peripheral blood. The patient received the VCA regimen (venetoclax, chidamide, and azacitidine) and was regularly monitored through blood counts, marrow cell morphology analysis, flow cytometry, and computed tomography or positron emission tomography-computed tomography imaging. After the first VCA course, the patient achieved a second CR with only transient myelosuppression. Following two VCA courses, he received chimeric antigen receptor T-cell therapy, which led to complete metabolic remission and improved prognosis. This case underscores the potential of the VCA regimen as a bridging therapy for EMR in B-ALL with MLL-AF4, although further studies are warranted. |
| format | Article |
| id | doaj-art-a5c7a5d9bf39430eb77c7b66320e2c9a |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a5c7a5d9bf39430eb77c7b66320e2c9a2025-01-14T06:10:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14759741475974Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature reviewXuelian JinZhigang LiuYu WuJie JiB-cell acute lymphoblastic leukemia (B-ALL) with the MLL-AF4 fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR). Herein, we present a case of a 46-year-old male patient who developed relapsed B-ALL with MLL-AF4. The patient initially achieved a complete remission (CR) after induction therapy and underwent haploidentical hematopoietic stem cell transplantation. Five months post-transplantation, he developed enlarged lymph nodes and subcutaneous masses. A lymph node biopsy confirmed EMR, without leukemia in the bone marrow or peripheral blood. The patient received the VCA regimen (venetoclax, chidamide, and azacitidine) and was regularly monitored through blood counts, marrow cell morphology analysis, flow cytometry, and computed tomography or positron emission tomography-computed tomography imaging. After the first VCA course, the patient achieved a second CR with only transient myelosuppression. Following two VCA courses, he received chimeric antigen receptor T-cell therapy, which led to complete metabolic remission and improved prognosis. This case underscores the potential of the VCA regimen as a bridging therapy for EMR in B-ALL with MLL-AF4, although further studies are warranted.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1475974/fullrelapsed/refractoryMLL-AF4ALLleukemiaBcl-2 inhibitor (venetoclax)histone deacetylase inhibitor (chidamide) |
| spellingShingle | Xuelian Jin Zhigang Liu Yu Wu Jie Ji Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review Frontiers in Immunology relapsed/refractory MLL-AF4 ALL leukemia Bcl-2 inhibitor (venetoclax) histone deacetylase inhibitor (chidamide) |
| title | Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review |
| title_full | Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review |
| title_fullStr | Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review |
| title_full_unstemmed | Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review |
| title_short | Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review |
| title_sort | venetoclax in combination with chidamide and azacitidine for the treatment of relapsed refractory b cell acute lymphoblastic leukemia with the mll af4 gene a case report and literature review |
| topic | relapsed/refractory MLL-AF4 ALL leukemia Bcl-2 inhibitor (venetoclax) histone deacetylase inhibitor (chidamide) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1475974/full |
| work_keys_str_mv | AT xuelianjin venetoclaxincombinationwithchidamideandazacitidineforthetreatmentofrelapsedrefractorybcellacutelymphoblasticleukemiawiththemllaf4geneacasereportandliteraturereview AT zhigangliu venetoclaxincombinationwithchidamideandazacitidineforthetreatmentofrelapsedrefractorybcellacutelymphoblasticleukemiawiththemllaf4geneacasereportandliteraturereview AT yuwu venetoclaxincombinationwithchidamideandazacitidineforthetreatmentofrelapsedrefractorybcellacutelymphoblasticleukemiawiththemllaf4geneacasereportandliteraturereview AT jieji venetoclaxincombinationwithchidamideandazacitidineforthetreatmentofrelapsedrefractorybcellacutelymphoblasticleukemiawiththemllaf4geneacasereportandliteraturereview |